Open Orphan PLC (AIM:ORPH, OTC:OPORF) chief executive Yamin ‘Mo’ Khan and Dr James Cummings, chief medical officer at Vaxart Inc, joined Proactive to talk about their plan to conduct a human challenge study next year to assess the efficacy of an Omnicron inoculation created by Vaxart that can be administered orally rather than via a jab.
After Open Orphan was the first company to run a COVID-19 challenge trial last year, Khan said it is a major milestone for its hVIVO subsidiary to work with Vaxart to develop the first global omicron challenge trial too.